Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
CAMBRIDGE, Mass., Feb. 04, 2016 -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, announced today that the company will participate in the Leerink Partners 5th Annual Global Healthcare Conference in New York City. Chief Executive Officer Mary Szela and Chief Financial and Administrative Officer Gregory Perry are scheduled to present in a fireside chat on Thursday, February 11, 2016 at 3:30 p.m. ET.
The presentation will be webcast live and may be accessed for up to 30 days following the conference by visiting the “Investors” section of Aegerion’s website, www.aegerion.com.
About Aegerion Pharmaceuticals
Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. For more information about the company, please visit www.aegerion.com.
CONTACT: Aegerion Pharmaceuticals, Inc. Amanda Murphy Associate Director, Investor Relations 857-242-5024
